trending Market Intelligence /marketintelligence/en/news-insights/trending/jtf8bjscj_rkf4uufucghq2 content esgSubNav
In This List

Acasti Pharma regains Nasdaq compliance

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond


Acasti Pharma regains Nasdaq compliance

Acasti Pharma Inc. said it regained compliance with a Nasdaq listing requirement that requires its shares to have a minimum bid price of $1.

The Canada-based developer of cardiovascular prescription drugs received the noncompliance notice in June.